C-Terminal Structure-Activity Relationships for the Novel Opioid Peptide JVA-901 (Venorphin)

  • Christy A. Sasiela
  • Marco A. Bennett
  • Thomas F. Murray
  • Jane V. Aldrich
Part of the American Peptide Symposia book series (APSY, volume 7)

Abstract

We previously reported a novel kappa opioid receptor antagonist JVA 901, now named venorphin, which was designed as a chimeric construct of a cobra venom tetrapeptide and [D-Ala8]dynorphin A(1–11)NH2 [1]. The N-terminal region of this new peptide exhibits structure-activity relationships (SAR) distinctly different from that of [D-Ala8]dynorphin A(1–11)NH2 [2]. Herein we explore the SAR of the C-terminal region of venorphin.

Keywords

Opioid Receptor Radioligand Binding Truncation Study Coupling Reagent Kappa Opioid Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Wan, Q., Murray, T.F., Aldrich, J.V. J. Med. Chem. 42, 3011–3013 (1999).PubMedCrossRefGoogle Scholar
  2. 2.
    Aldrich, J.V., Sasiela, C.A., Wan, Q., Murray, T.F., manuscript in preparation.Google Scholar
  3. 3.
    Attamangkul, S., Ishmael, J.E., Murray, T.F., Grandy, D.K., DeLander, G.E., Keiffer, B.L., Aldrich, J.V. J. Med. Chem. 40, 1211 (1997).CrossRefGoogle Scholar
  4. 4.
    Turcotte, A., Lalonde, J.M., St. Pirerre, J.M., Lemaire, S. Int. J. Peptide Protein Res. 23, 361–367 (1984).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2001

Authors and Affiliations

  • Christy A. Sasiela
    • 1
  • Marco A. Bennett
    • 1
  • Thomas F. Murray
    • 2
  • Jane V. Aldrich
    • 1
  1. 1.Department of Pharmaceutical SciencesUniversity of Maryland School of PharmacyBaltimoreUSA
  2. 2.Department of Physiology and Pharmacology, College of Veterinary MedicineUniversity of GeorgiaAthensUSA

Personalised recommendations